Get access

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies*

Authors


  • *

    Presented, in part, at the 19th International Congress of the Transplantation Society, Miami, FL, USA (August 25–30, 2002).

Timothy Mathew, MD, Renal Unit Ward 3C, Queen Elizabeth Hospital, 28 Woodville Road, Woodville South SA, Adelaide, 5011, Australia.
Tel.: 618-8334-7555; fax: 618-8334-7540;
e-mail: tmathew@bigpond.net.au

Abstract

Abstract:  We examined the rates of malignancy at 2 yr after transplantation in renal allograft patients receiving sirolimus (SRL) in continuous combination with cyclosporine (CsA), SRL as base therapy or SRL maintenance therapy after early withdrawal of CsA. A total of 1295 patients were enrolled in two double-blind studies comparing SRL with azathioprine (AZA) or placebo administered in continuous regimens with CsA. In two other trials (n = 161), SRL given as base therapy was compared with CsA. In the fifth trial, patients were randomly assigned at 3 months to either remain on CsA + SRL therapy (n = 215) or to have CsA eliminated with SRL being continued in concentration-controlled doses (n = 215). At 2 yr after transplantation, patients receiving SRL in continuous combination with CsA had a significantly lower incidence of skin cancer compared with patients receiving placebo. Patients receiving SRL as base therapy had no malignancies compared with a 5% incidence in those receiving CsA. The incidence of malignancy was significantly lower in patients receiving concentration-controlled SRL with elimination of CsA compared with those who remained on CsA + SRL. Based on the currently available data, patients receiving SRL-based therapy without CsA or SRL maintenance therapy after early CsA withdrawal have lower rates of malignancy in the first 2 yr after renal transplantation. SRL immunotherapy may be beneficial in protecting renal transplant patients from skin cancer even when given in combination with CsA.

Ancillary